Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Trainee perceptions of digital dermatopathology implementation at a multisite academic institution
Reinhart, Jacob P. , Proffer, Sydney L. , Gerdes, Erin Wissler, Cervenka, Derek J., Peters, Margot S. , Comfere, Nneka I. , Johnson, Emma F. , Wieland, Carilyn N. , Gerdes, Erin O. Wissler , Cervenka, Derek, Comfere, Nneka , Larkin, Sydney C , Wissler Gerdes, Erin O , Reinhart, Jacob , Ridgeway, Jennifer L. , Barry, Barbara , Kamath, Celia

Mayo Clinic

Journal of Cutaneous Pathology | July 5, 2024 | Volume: 51 | Issue: 12 | Pages: 922-924

10.1111/cup.14681 | PMID 38967247 Get It

O-110 Adenomyosis : the challenge of classification and diagnosis
Sanie, S As, Wilde, R L De, Gordts, S, Guo, S -W, Keckstein, J, Nisolle, Michelle , Johnson, NP, Grimbizis, Grigoris , Féki, Anis , Acién, Maribel , Wilde, Rudy Leon De , Guo, S -W, Keckstein, J, Laganà, Antonio Simone , Maggiore, Umberto Leone Roberti , SARIDOĞAN, Erdinç , Stewart, Elizabeth A. , Tellum, Tina , Tomassetti, Carla , Clef, Nathalie Le

Mayo Clinic

Human Reproduction | July 3, 2024 | Volume: 39 | Issue: Supplement_1 | Pages: No page available

10.1093/humrep/deae108.121 Get It

Abstract Study question What does the collaborative document on adenomyosis terminology, classification, and diagnosis by ESGE, ESHRE, and WES provides? Summary answer This good practice recommendations paper offers guidance on the technical aspects, terminology, classification, and diagnosis of adenomyosis in women of reproductive age. What is known already The existing literature on adenomyosis terminology is heterogeneous and confusing. Various classification systems based on ultrasound and MRI have been proposed, yet none have gained international acceptance or clinical validation. The contradictory data on the diagnostic accuracy of these modalities further complicate adenomyosis diagnosis in reproductive-age women. Study design, size, duration A working group from ESGE, ESHRE, and WES has collaborated to write recommendations concerning the terminology, classification, and diagnosis of adenomyosis. Participants/materials, setting, methods Focusing on terminology, classification, and diagnosis, this good practice paper paves the way for further recommendations on the management and surgical treatment of adenomyosis in reproductive-age women. Main results and the role of chance The document overviews adenomyosis terminology and reviews proposed classification systems based on histology, ultrasound, and MRI, concluding with diagnostic recommendations. Limitations, reason for caution Owing the scarcity of evidence, these recommendations predominantly rely on clinical expertise. Wider implications of the findings The recommendations aim to enhance existing adenomyosis guidelines. Study funding/Competing interests All costs were covered by ESHRE funds, with no external funding for the development process or manuscript production.
Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH).
Talukder, Rafee , Hobeika, Charbel, Johnson, Jeffrey S. , Castaneda, D.H. Marmolejo , Zakopoulou, Roubini , Hui, Gavin , Buznego, Lucía Andrea Alonso , Stewart, Tyler F. , Grivas, Petros , Bakaloudi, Dimitra Rafailia , Makrakis, Dimitrios , Diamantopoulos, Leonidas Nikolaos , Jindal, Tanya , Nguyen, Charles B. , Hobeika, Charbel S. , Thomas, Vinay Mathew , Korolewicz, James , Barata, Pedro C. , Brown, Jason R. , Epstein, Ilana Bensussen , Khaki, Ali Raza

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 4580-4580

10.1200/jco.2024.42.16_suppl.4580 Get It

4580 Background: ICIs are used for UC in different settings. Most cases have pure urothelial carcinoma (PUC) but about a third have UC mixed with SH. We examined pts with UC treated with ICI and hypothesized that outcomes would not differ between PUC and mixed with SH. Methods: We retrospectively included pts with PUC and any SH component treated with ICI as adjuvant, 1st line [1L] upfront, maintenance avelumab [mAV], ≥2nd line [2+L] therapy; pts were divided by SH type. Pts with multiple SH were included as separate group. We excluded pts with pure non-UC histology and pts treated with neoadjuvant ICI. We calculated overall response rate (ORR), median overall, progression-free and disease-free survival [mOS, mPFS, mDFS] using KM method from ICI start. Analysis was stratified by therapy line; multivariable models were adjusted by Khaki factors for 1L/upfront, mAV and Bellmunt factors for 2+L; reference group was PUC. We used descriptive statistics for small subsets. Results: We included 1525 pts from 26 sites; n=752 1L, n=609 2+L; 76% men, 80% White, 69% smoking history, 80% lower urinary tract primary, 28% SH. Median f/u time from 1L ICI start 24 months (mo): mPFS was 3 (95%CI 2.8-3.2) mo for PUC (n=340), 3 (95%CI 2-4) mo for squamous (n=60) (HR=1, [95%CI 0.7-1.4]), 2 (95%CI 1.4-3.2) mo for micropapillary (n=36) (HR=1.3 [95% 0.9-2]) and 4 (3.5-4.5) mo for ≥2 SH (n=20) (HR=0.9 [95%CI 0.6-1.5]). Median f/u time from 2+L ICI start 26 mo: mPFS was 3 (95%CI 2.4-3.2) mo for PUC (n=264), 4 (95%CI 2-5) mo for squamous (n=33) (HR=0.8, [95%CI 0.6-1.2]), 3 (95%CI 1.6-3.7) mo for micropapillary (n=17) (HR=0.9 [95% 0.6-1.7]) and 3 (2.5-3.1) mo for ≥2 SH (n=10) (HR=1.2 [95%CI 0.6-2.2]); Table shows ORR/OS data. Data on adjuvant and mAV settings will also be presented. Conclusions: We found no significant survival difference between PUC and SH. ORR was numerically higher with sarcomatoid SH and ≥2 SH in the 1L upfront setting. Limitations: retrospective design, small sample size in a few subsets, lack of randomization and central scan/path (% SH) review, selection bias, unmeasured confounders. [Table: see text]
Cost analysis of targeted and immunotherapies in operable esophageal and non-small cell lung cancers.
Alwatari, Yahya , Shanshal, Mohamed , Johnson, Nate C., Thao, Viengneesee , Borah, Bijan J. , Shen, Robert K.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8051-8051

10.1200/jco.2024.42.16_suppl.8051 Get It

8051 Background: The National Comprehensive Cancer Network (NCCN) currently recommends the use of Atezolizumab, Nivolumab, Osimertinib, and Pembrolizumab in the perioperative management of non-small cell lung cancers (NSCLC) and esophageal cancers (EC). As the therapeutic landscape evolves, we aim to evaluate the cost implications of these guidelines for eligible patients in the United States. Methods: The Medicare Part B payment allowance limits of each medication were ascertained except Osimertinib for which an approximate wholesale acquisition cost (WAC) was reported due to privately administered Medicare Part D coverage. Using national data and published literature, we estimated the annual incidence of patients with newly diagnosed EC and NSCLC who would be eligible for surgery combined with neoadjuvant and/or adjuvant immune and targeted therapy. We applied the estimated cost of the medication based on dosing and duration of treatment, which spanned 1 year for all but adjuvant Osimertinib, which spanned 3 years. Using these data, the cost per patient and the total cost for an incident cohort were estimated. Results: We estimated that 8,602 patients with newly diagnosed EC would be eligible for adjuvant Nivolumab; the cost to treat one patient was $248,529, and the cost to treat one incident cohort was approximately $2 billion (Table). We estimated that 50,409 patients with NSCLC will meet the criteria for neoadjuvant Nivolumab with a total cost of three cycles of $32,894 per patient and $1.7 billion per cohort. Among NSCLC patients who may undergo resection and qualify for adjuvant therapy (Stage IB – IIA with high-risk features or IIB-IIIA), 85,063 patients are anticipated to be EGFR-negative and treated with adjuvant Atezolizumab or Pembrolizumab. Treatment costs range from $178,584 – $197,320 per patient with up to $16 billion cost per cohort. The cost to treat one patient with adjuvant Osimertinib was $556,720, and the cost to treat one incident cohort was close to $10 billion. In total, the cost to treat an incident cohort of eligible operable thoracic malignancies could exceed $30 billion. Conclusions: Neoadjuvant and adjuvant immune and targeted therapy in operable thoracic patients is associated with a significant cost burden. Prospective large-scale studies are needed to assess cost-effectiveness, particularly given the paucity of superior overall survival data with these agents. [Table: see text]
Glycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis
Khanal, Shalil , Liu, Yuanhang , Wixom, Alexander Q. , Washington, Alexander M. , Jalan‐Sakrikar, Nidhi , Cooper, Shawna A. , Vučković, Ivan , Zhang, Song , Zhong, Jun , Johnson, Kenneth L. , Charlesworth, M. Cristine , Kim, I.Y. , Yeon, Yubin, Yoon, Sangwoong , Noh, Yung‐Kyun , Meroueh, Chady , Timbilla, Abdul Aziz , Yaqoob, Usman , Gao, Jinhang , Kim, Yohan , Hay, Nissim , Shah, Vijay H. , Bamidele, Adebowale O , Wixom, Alexander Q , Washington, Alexander M , Sakrikar, Nidhi Jalan , Cooper, Shawna A , Vuckovic, Ivan , Zhang, Song , Zhong, Jun , Johnson, Kenneth , Kim, Iljung , Yeon, Yubin , Yoon, Sangwoong , Noh, Yung-Kyun , Meroueh, Chady , Timbilla, Abdul Aziz , Gao, Jinhang , Kim, Yo Han , Lucien, Fabrice , Simons, Michael , Shah, Vijay H , Kostallari, Enis , Liu, Yuanhang, Bamidele, Adebowale O. , Charlesworth, M. Cristine , Yaqoob, Usman , Lucien, Fabrice , Huebert, Robert C. , Simons, Michael , Kostallari, Enis

Mayo Clinic

Science Advances | June 28, 2024 | Volume: 10 | Issue: 26 | Pages: No page available

10.1126/sciadv.adn5228 | PMID 38941469 Get It

Liver fibrosis is characterized by the activation of perivascular hepatic stellate cells (HSCs), the release of fibrogenic nanosized extracellular vesicles (EVs), and increased HSC glycolysis. Nevertheless, how glycolysis in HSCs coordinates fibrosis amplification through tissue zone-specific pathways remains elusive. Here, we demonstrate that HSC-specific genetic inhibition of glycolysis reduced liver fibrosis. Moreover, spatial transcriptomics revealed a fibrosis-mediated up-regulation of EV-related pathways in the liver pericentral zone, which was abrogated by glycolysis genetic inhibition. Mechanistically, glycolysis in HSCs up-regulated the expression of EV-related genes such as Ras-related protein Rab-31 ( RAB31 ) by enhancing histone 3 lysine 9 acetylation on the promoter region, which increased EV release. Functionally, these glycolysis-dependent EVs increased fibrotic gene expression in recipient HSC. Furthermore, EVs derived from glycolysis-deficient mice abrogated liver fibrosis amplification in contrast to glycolysis-competent mouse EVs. In summary, glycolysis in HSCs amplifies liver fibrosis by promoting fibrogenic EV release in the hepatic pericentral zone, which represents a potential therapeutic target.
Addressing Disparities in Pediatric Congenital Heart Disease: A Call for Equitable Health Care
Chowdhury, Devyani , Elliott, Pietro , Asaki, S. Yukiko , Amdani, Shahnawaz , Nguyen, Quang‐Tuyen , Ronai, Christina , Tierney, Seda , Levy, Victor Y. , Puri, Kriti , Altman, Carolyn A. , Johnson, Jonathan N. , Glickstein, Julie S. , Elliott, Pietro , Ronai, Christina

Mayo Clinic

Journal of the American Heart Association | June 27, 2024 | Volume: 13 | Issue: 13 | Pages: No page available

10.1161/jaha.123.032415 | PMID 38934870 Get It

While significant progress has been made in reducing disparities within the US health care system, notable gaps remain. This article explores existing disparities within pediatric congenital heart disease care. Congenital heart disease, the most common birth defect and a leading cause of infant death, has garnered substantial attention, revealing certain disparities within the US health care system. Factors such as race, ethnicity, insurance coverage, socioeconomic status, and geographic location are all commonalities that significantly affect health disparities in pediatric congenital heart disease. This comprehensive review sheds light on disparities from diverse perspectives in pediatric care, demonstrates the inequities and inequalities leading to these disparities, presents effective solutions, and issues a call to action for providers, institutions, and the health care system. Recognizing and addressing these disparities is imperative for ensuring equitable care and enhancing the long‐term well‐being of children affected by congenital heart disease. Implementing robust, evidence‐based frameworks that promote responsible and safe interventions is fundamental to enduring change.
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel
Fonseca, Rafaël , Rossi, Adriana , Medhekar, Rohan , Voelker, Jennifer , Homan, Trevor, Wilcock, Jessica, Karakusevic, Anna , Cochrane, J.C., Bridge, Daisy, Perry, Richard , Kaila, Shuchita, Rossi, Adriana , Fonseca, Rafael , Cochrane, James, Perry, Richard, Davies, Faith E.

Mayo Clinic

Future Oncology | June 24, 2024 | Volume: 20 | Issue: 23 | Pages: 1645-1656

10.1080/14796694.2024.2342228 | PMID 38861282 Get It

Genotypic and phenotypic characterization of Enterococcus faecalis isolates from periprosthetic joint infections
Haeberle, Amanda L. , Greenwood‐Quaintance, Kerryl E. , Zar, Sarah, Patel, Robin , Willett, Julia L. E. , Patel, Robin , Willett, Julia L E , Greenwood-Quaintance, Kerryl , Johnson, Stephen A.

Mayo Clinic

Microbiology Spectrum | June 24, 2024 | Volume: 12 | Issue: 8 | Pages: No page available

10.1128/spectrum.00565-24 | PMID 38912797 Get It

ABSTRACT Over 2.5 million prosthetic joint implantation surgeries occur annually in the United States. Periprosthetic joint infections (PJIs), though occurring in only 1–2% of patients receiving replacement joints, are challenging to diagnose and treat and are associated with significant morbidity. The Gram-positive bacterium Enterococcus faecalis , which can be highly antibiotic-resistant and is a robust biofilm producer on indwelling medical devices, accounts for 2–11% of PJIs. E. faecalis PJIs are understudied compared to those caused by other pathogens, such as Staphylococcus aureus . This motivates the need to generate a comprehensive understanding of E. faecalis PJIs to guide future treatments for these infections. To address this, we describe a panel of E. faecalis strains isolated from the surface of prosthetic joints in a cohort of individuals treated at the Mayo Clinic in Rochester, MN. Here, we present the first complete genome assemblage of E. faecalis PJI isolates. Comparative genomics shows differences in genome size, virulence factors, antimicrobial resistance genes, plasmids, and prophages, underscoring the genetic diversity of these strains. These isolates have strain-specific differences in in vitro biofilm biomass, biofilm burden, and biofilm morphology. We measured robust changes in biofilm architecture and aggregation for all isolates when grown in simulated synovial fluid (SSF). Finally, we evaluated the antibiotic efficacy of these isolates and found strain-specific changes across all strains when grown in SSF. Results of this study highlight the existence of genetic and phenotypic heterogeneity among E. faecalis PJI isolates which will provide valuable insight and resources for future E. faecalis PJI research. IMPORTANCE Periprosthetic joint infections (PJIs) affect ~1–2% of those who undergo joint replacement surgery. Enterococcus faecalis is a Gram-positive opportunistic pathogen that causes ~10% of PJIs in the United States each year, but our understanding of how and why E. faecalis causes PJIs is limited. E. faecalis infections are typically biofilm-associated and can be difficult to clear with antibiotic therapy. Here, we provide complete genomes for four E. faecalis PJI isolates from the Mayo Clinic. These isolates have strain-specific differences in biofilm formation, aggregation, and antibiotic susceptibility in simulated synovial fluid. These results provide important insight into the genomic and phenotypic features of E. faecalis isolates from PJI.
White Matter Abnormalities Track Disease Progression in Multiple System Atrophy
Raghavan, Sheelakumari , Lesnick, Timothy G. , Fought, Angela J. , Thostenson, Kaely, Sparrman, Kohl L. Johnson, Gehrking, Tonette L., Gehrking, Jade A., Sletten, David M., Low, Phillip A. , Thostenson, Kaely B, Johnson Sparrman, Kohl L, Singer, Wolfgang , Vemuri, Prashanthi , Castillo, Anna , Reid, Robert I. , Vemuri, Prashanthi

Mayo Clinic

Movement Disorders Clinical Practice | June 24, 2024 | Volume: 11 | Issue: 9 | Pages: 1085-1094

10.1002/mdc3.14147 | PMID 38923361 Get It

Abstract Background White matter (WM) abnormalities have been implicated in clinically relevant functional decline in multiple system atrophy (MSA). Objective To identify the WM and gray matter (GM) abnormalities in MSA and assess the utility of longitudinal structural and diffusion changes as surrogate markers for tracking disease progression in MSA. Methods Twenty‐seven participants with early MSA [15 with clinically predominant cerebellar (MSA‐C) and 12 with clinically predominant parkinsonian features (MSA‐P)] and 14 controls were enrolled as a part of our prospective, longitudinal study of synucleinopathies. Using structural magnetic resonance imaging (MRI) and diffusion MRI (diffusion tensor and neurite orientation and dispersion density imaging), we analyzed whole and regional brain changes in these participants. We also evaluated temporal imaging trajectories based on up to three annual follow‐up scans and assessed the impact of baseline diagnosis on these imaging biomarkers using mixed‐effect models. Results MSA patients exhibited more widespread WM changes than GM, particularly in the cerebellum and brainstem, with greater severity in MSA‐C. Structural and diffusion measures in the cerebellum WM and brainstem deteriorated with disease progression. Rates of progression of these abnormalities were similar in both MSA subtypes, reflecting increasing overlap of clinical features over time. Conclusion WM abnormalities are core features of MSA disease progression and advance at similar rates in clinical MSA subtypes. Multimodal MRI imaging reveals novel insights into the distribution and pattern of brain abnormalities and their progression in MSA. Selected structural and diffusion measures may be useful for tracking disease progression in MSA clinical trials.
Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1
Shirani, Mahsa , Levin, Solomon , Shebl, Bassem , Requena, David , Finkelstein, Tova M. , Johnson, Daniel S. , Ng, Denise , Heissel, Søren , Højrup, Peter , Molina, Henrik , Rice, Charles M. , Lyons, Barbara A. , Simon, Sanford M. , Lalazar, Gadi , Heissel, Søren , Hojrup, Peter , Molina, Henrik , de Jong, Ype P , Rice, Charles M , Singhi, Aatur Dilip , Torbenson, Michael S , Coffino, Philip , Lyons, Barbara , Simon, Sanford M , Requena, David , Levin, Solomon N , Jong, Ype P. de , Torbenson, Michael

Mayo Clinic

Cancer Research | June 18, 2024 | Volume: 84 | Issue: 16 | Pages: 2626-2644

10.1158/0008-5472.can-23-4110 | PMID 38888469 Get It

Abstract Fibrolamellar hepatocellular carcinoma (FLC) is a rare liver cancer that is driven by the fusion of DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). PKA activity is controlled through regulatory proteins that both inhibit catalytic activity and control localization, and an excess of regulatory subunits ensures PRKACA activity is inhibited. Here, we found an increase in the ratio of catalytic to regulatory units in FLC patient tumors driven by DNAJB1::PRKACA using mass spectrometry, biochemistry, and immunofluorescence, with increased nuclear localization of the kinase. Overexpression of DNAJB1::PRKACA, ATP1B1::PRKACA, or PRKACA, but not catalytically inactive kinase, caused similar transcriptomic changes in primary human hepatocytes, recapitulating the changes observed in FLC. Consistently, tumors in patients missing a regulatory subunit or harboring an ATP1B1::PRKACA fusion were indistinguishable from FLC based on the histopathological, transcriptomic, and drug–response profiles. Together, these findings indicate that the DNAJB1 domain of DNAJB1::PRKACA is not required for FLC. Instead, changes in PKA activity and localization determine the FLC phenotype. Significance: Alterations leading to unconstrained protein kinase A signaling, regardless of the presence or absence of PRKACA fusions, drive the phenotypes of fibrolamellar hepatocellular carcinoma, reshaping understanding of the pathogenesis of this rare liver cancer.